Skip to main content

Advertisement

SpringerLink
Log in

Thymidylate synthase pharmacogenetics

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Thymidylate synthase (TYMS) is an important target for chemotherapy drugs, such as 5-fluorouracil (5FU) and methotrexate. Over-expression of TYMS is linked to resistance to TYMS-targeted chemotherapy drugs. Currently there is no protocol for selecting cancer patients at risk for drug resistance prior to chemotherapy treatment. Three polymorphisms in the 5′ and 3′ untranslated regions (5′UTR and 3′UTR) of the thymidylate synthase gene have been shown to influence TYMS expression. Preliminary data has suggested a poorer response rate to 5FU or methotrexate is seen in patients with 3 copies of a 28 bp tandem repeat in the 5′UTR enhancer region (TSER polymorphism) and this relationship may be further clarified by the presence of a single nucleotide polymorphism (SNP) with the second repeat of the 3 repeat (TSER*3) allele. A 6 bp deletion in the 3′UTR of the TYMS gene has also been shown to affect TYMS RNA expression and has a significant association with poor outcome in 5FU treated patients. Evidence linking all 3 TYMS polymorphisms with TYMS expression and patient response to TYMS-targeted chemotherapy treatment will be highlighted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Evans WE, McLeod HL: Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med 348: 538–549, 2003

    Article  CAS  PubMed  Google Scholar 

  2. Marsh S, McLeod HL: Cancer Pharmacogenetics. Br J Cancer (in press), 2003

  3. Watters JW, McLeod HL: Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 1603: 99–111, 2003

    CAS  PubMed  Google Scholar 

  4. Watters JW, McLeod HL: Recent advances in the pharmacogenetics of cancer chemotherapy. Curr Opin Mol Ther 4: 565–571, 2002

    CAS  PubMed  Google Scholar 

  5. Johnston PG, Drake JC, Trepel J, Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306–4312, 1992

    CAS  PubMed  Google Scholar 

  6. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407–1412, 1995

    CAS  PubMed  Google Scholar 

  7. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223–3229, 1997

    CAS  PubMed  Google Scholar 

  8. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simmoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Allegra CJ, Johnston PG: Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923–1931, 1997

    CAS  PubMed  Google Scholar 

  9. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176–182, 1996

    CAS  PubMed  Google Scholar 

  10. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760–1770, 1999

    CAS  PubMed  Google Scholar 

  11. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640–2647, 1994

    CAS  PubMed  Google Scholar 

  12. Kornmann M, Link KH, Lenz HJ, Pillasch J, Metzger R, Butzer U, Leder GH, Weindel M, Safi F, Danenberg KD, Beger HG, Danenberg PV: Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 118: 29–35, 1997

    Article  CAS  PubMed  Google Scholar 

  13. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20: 191–197, 1995

    CAS  PubMed  Google Scholar 

  14. Kawakami K, Salonga D, Omura K, Park J, Danenberg K, Watanabe Y, Danenberg P: Effects of polymorphic tandem repeat sequence on the in vitro translation of messenger RNA (Abstract). Proc Am Assoc Cancer Res 40: 436–437, 1999

    Google Scholar 

  15. Kawakami K, Omura K, Kanehira E, Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19: 3249–3252, 1999

    CAS  PubMed  Google Scholar 

  16. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1: 65–70, 2001

    CAS  PubMed  Google Scholar 

  17. Takeishi K, Kaneda S, Ayusawa D, Shimizu K, Gotoh O, Seno T: Human thymidylate synthase gene: Isolation of phage clones which cover a functionally active gene and structural analysis of the region upstream from the translation initiation codon. J Biochem 106: 575–583, 1989

    CAS  PubMed  Google Scholar 

  18. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T, Altman S: Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res 15: 1259–1270, 1987

    CAS  PubMed  Google Scholar 

  19. Kaneda S, Horie N, Takeishi K, Takayanagi A, Seno T, Ayusawa D: Regulatory sequences clustered at the 5′ end of the first intron of the human thymidylate synthase gene function in cooperation with the promoter region. Somat Cell Mol Genet 18: 409–415, 1992

    Article  CAS  PubMed  Google Scholar 

  20. Kaneda S, Nalbantoglu J, Takeishi K, Shimizu K, Gotoh O, Seno T, Ayusawa D: Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem 265: 20277–20284, 1990

    CAS  PubMed  Google Scholar 

  21. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63: 2898–2904, 2003

    CAS  PubMed  Google Scholar 

  22. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, Omura K, Watanabe G, Danenberg PV: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7: 4096–4101, 2001

    CAS  PubMed  Google Scholar 

  23. Marsh S, McKay JA, Cassidy J, McLeod HL: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19: 383–386, 2001

    CAS  PubMed  Google Scholar 

  24. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Martinez Monge R, Salgado E, Angeletti S, Brugarolas A: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19: 1779–1786, 2001

    CAS  PubMed  Google Scholar 

  25. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85: 827–830, 2001

    Article  CAS  PubMed  Google Scholar 

  26. Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, Komatsu H, Shindou H, Fukuoka H, Yoshinaga M, Shibasaki S, Nanashima A, Yamaguchi H, Yasutake T, Tagawa Y: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 9: 3700–3704, 2003

    CAS  PubMed  Google Scholar 

  27. Krajinovic M, Costea I, Chiasson S: Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 359: 1033–1034, 2002

    Article  CAS  PubMed  Google Scholar 

  28. Costea I, Moghrabi A, Krajinovic M: The influence of cyclin D1 (CCND1) 870A > G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics 13: 577–580, 2003

    CAS  PubMed  Google Scholar 

  29. Luo HR, Lu XM, Yao YG, Horie N, Takeishi K, Jorde LB, Zhang YP: Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem Genet 40: 41–51, 2002

    Article  CAS  PubMed  Google Scholar 

  30. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58: 310–312, 1999

    Article  CAS  PubMed  Google Scholar 

  31. Marsh S, Ameyaw MM, Githang'a J, Indalo A, Ofori-Adjei D, McLeod HL: Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 16: 528, 2000

    Article  CAS  PubMed  Google Scholar 

  32. Pullarkat S-T, Ingles S, Marsh S, Xiong YP, Habashy M, Lenz H-J: Analysis on thymidylate synthase gene polymorphisms in the Latino population (Abstract). Proc Am Assoc Cancer Res 40: 468, 1999

    Google Scholar 

  33. Marsh S, McLeod HL: Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 1: 175–178; discussion 179–181, 2001

    CAS  PubMed  Google Scholar 

  34. Kawakami K, Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63: 6004–6007, 2003

    CAS  PubMed  Google Scholar 

  35. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9: 1381–1385, 2000

    CAS  PubMed  Google Scholar 

  36. Lenz H-J, Zhang W, Zahedy S, Gil J, Yu M, Stoehlmacher J: A 6 base-pair deletion in the 3 UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors. A possible candidate gene for colorectal cancer risk (Abstract). Proc Am Assoc Cancer Res 43: 660, 2002

    Google Scholar 

  37. McLeod H, Sargent D, Marsh S, Fuchs C, Ramanathan R, Williamson S, Findlay B, Thibodeau S, Petersen G, Goldberg R: Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer (Abstract). Proc Am Assoc Clin Oncol 22: 252, 2003

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Molecular Oncology, Washington University School of Medicine in St. Louis, 660, South Euclid Avenue, Campus Box 8069, St. Louis, MO, 63110, USA

    Sharon Marsh

Authors
  1. Sharon Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharon Marsh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marsh, S. Thymidylate synthase pharmacogenetics. Invest New Drugs 23, 533–537 (2005). https://doi.org/10.1007/s10637-005-4021-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-005-4021-7

Key words

Search

Navigation